Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.
Ishido S, Tamaki N, Takahashi Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Tsuchiya K, Nakanishi H, Kurosaki M, Izumi N. Ishido S, et al. Among authors: maeyashiki c. BMC Gastroenterol. 2023 Jun 17;23(1):211. doi: 10.1186/s12876-023-02848-7. BMC Gastroenterol. 2023. PMID: 37330485 Free PMC article.
RIPK3 regulates p62-LC3 complex formation via the caspase-8-dependent cleavage of p62.
Matsuzawa Y, Oshima S, Nibe Y, Kobayashi M, Maeyashiki C, Nemoto Y, Nagaishi T, Okamoto R, Tsuchiya K, Nakamura T, Watanabe M. Matsuzawa Y, et al. Among authors: maeyashiki c. Biochem Biophys Res Commun. 2015 Jan 2;456(1):298-304. doi: 10.1016/j.bbrc.2014.11.075. Epub 2014 Nov 24. Biochem Biophys Res Commun. 2015. PMID: 25450619
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib.
Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Kaneko S, et al. Among authors: maeyashiki c. Hepatol Res. 2020 Jan;50(1):137-143. doi: 10.1111/hepr.13416. Epub 2019 Sep 6. Hepatol Res. 2020. PMID: 31349377
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma.
Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, Kaneko S, Takaura K, Higuchi M, Okada M, Wang W, Osawa L, Sekiguchi S, Hayakawa Y, Yamashita K, Enomoto N, Izumi N. Takada H, et al. Among authors: maeyashiki c. Cancers (Basel). 2019 Aug 27;11(9):1256. doi: 10.3390/cancers11091256. Cancers (Basel). 2019. PMID: 31461985 Free PMC article.
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Wang W, et al. Among authors: maeyashiki c. Cancers (Basel). 2019 Oct 9;11(10):1517. doi: 10.3390/cancers11101517. Cancers (Basel). 2019. PMID: 31601010 Free PMC article.
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Kirino S, et al. Among authors: maeyashiki c. J Gastroenterol Hepatol. 2020 Sep;35(9):1595-1601. doi: 10.1111/jgh.14990. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31975419
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Takahashi Y, Izumi N. Tamaki N, et al. Among authors: maeyashiki c. J Med Virol. 2020 Aug;92(8):1355-1358. doi: 10.1002/jmv.25692. Epub 2020 Feb 7. J Med Virol. 2020. PMID: 31994737
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Kirino S, et al. Among authors: maeyashiki c. PLoS One. 2020 Apr 20;15(4):e0231828. doi: 10.1371/journal.pone.0231828. eCollection 2020. PLoS One. 2020. PMID: 32310967 Free PMC article.
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir.
Tamaki N, Kurosaki M, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: maeyashiki c. JGH Open. 2019 Oct 24;4(3):429-432. doi: 10.1002/jgh3.12273. eCollection 2020 Jun. JGH Open. 2019. PMID: 32514449 Free PMC article.
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis.
Tamaki N, Kurosaki M, Higuchi M, Kirino S, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Izumi N. Tamaki N, et al. Among authors: maeyashiki c. Hepatol Res. 2020 Aug;50(8):996-999. doi: 10.1111/hepr.13533. Epub 2020 Jul 13. Hepatol Res. 2020. PMID: 32515534
56 results